Biogen’s partner, Japan-based Eisai, leads the clinical development and regulatory submissions for Leqembi. Though both companies co-commercialize and co-promote the drug, Eisai has the final ...

Nine months after the U.S. launch of Eisai Limited (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Leqembi, the first drug shown to slow Alzheimer’s progression, adoption faces hurdles due to ...

Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.

In a widely-anticipated study, Eisai and Biogen on Tuesday said their Alzheimer's drug slowed cognitive decline among people with early signs of the disease. The study, led by Eisai, which has ...

Non-APOE4 carriers do not benefit from treatment with lecanemab, which reduces the rate of progression of APOE4 carriers. Read more here.

Eisai and Biogen get another chance. Read why the latest from the two companies is a big step forward even though it's still just a glimmer of hope for Alzheimer’s sufferers.

Biogen and its partner Eisai said Tuesday night that their experimental Alzheimer’s disease therapy successfully slowed the memory-robbing condition in a large clinical trial. The results set ...

Eisai and Biogen said on Saturday the Japanese drugmaker had applied for full FDA approval of the drug. Sign up here. The drug, to be sold under the brand Leqembi, belongs to a class of treatments ...

Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi (lecanemab) for early Alzheimer’s disease (AD).